Microbot Medical stock trades near its yearly low

Microbot Medical stock (US5950101098) traded at USD 0.46 on Nasdaq on September 22, 2026, leaving the company with a market capitalization of USD 12.8 million. The quoted 52-week range of USD 0.38 to USD 2.10 places the shares USD 0.08 above the low and USD 1.64 below the high.

Micro-cap valuation shapes the picture

The numerical distance between the current price and the 52-week extremes is the clearest market signal available for Microbot Medical. At USD 0.46, the stock is 21.1 percent above its 52-week low and 78.1 percent below its 52-week high, based on the Nasdaq snapshot dated September 22, 2026.

The USD 12.8 million market capitalization also puts the company in the micro-cap segment. That valuation makes individual financing, clinical and regulatory milestones material for the share price because small absolute changes in equity value can translate into large percentage movements.

Nasdaq liquidity remains central

Microbot Medical trades on Nasdaq in USD, and the September 22, 2026 quotation provides the primary reference for the stock. The price and range are market figures rather than operating results, so they describe the market's current valuation without substituting for quarterly revenue, earnings or cash-flow data.

For investors assessing the company, the comparison is straightforward: the USD 0.46 quote is closer to the USD 0.38 yearly low than to the USD 2.10 high, while the market value remains below USD 13 million. Those figures frame the stock as a highly small-cap medical technology security whose valuation is sensitive to company-specific developments.

Stock remains below USD 1

Microbot Medical stock stood at USD 0.46 on Nasdaq as of September 22, 2026. The same dated market context records a USD 12.8 million market capitalization and a 52-week span from USD 0.38 to USD 2.10.

More news and analyses on Microbot Medical stock